1.63
-0.045(-2.69%)
Currency In USD
| Previous Close | 1.67 |
| Open | 1.64 |
| Day High | 1.68 |
| Day Low | 1.6 |
| 52-Week High | 46 |
| 52-Week Low | 1.52 |
| Volume | 34,158 |
| Average Volume | 133,142 |
| Market Cap | 4M |
| PE | -0.25 |
| EPS | -6.46 |
| Moving Average 50 Days | 1.86 |
| Moving Average 200 Days | 6.19 |
| Change | -0.05 |
If you invested $1000 in Autonomix Medical, Inc. Common Stock (AMIX) since IPO date, it would be worth $16.03 as of June 01, 2025 at a share price of $1.625. Whereas If you bought $1000 worth of Autonomix Medical, Inc. Common Stock (AMIX) shares 6 months ago, it would be worth $362.72 as of June 01, 2025 at a share price of $1.625.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology
GlobeNewswire Inc.
May 15, 2025 12:30 PM GMT
Patent strengthens Autonomix’s intellectual property position in the nerve-mapping and denervation space, supporting the Company’s broader mission to advance minimally invasive, nerve-focused therapeutics Company continues to expand its growing globa
Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event
GlobeNewswire Inc.
May 14, 2025 1:20 PM GMT
Live webcast followed by an interactive Q&A session on Thursday, May 22nd at 4:00 PM ET Access the event here THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical devi
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market
GlobeNewswire Inc.
May 13, 2025 1:20 PM GMT
Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Access Here Additional indications potentially double the addressable market beyond pancreatic cancer